Zevra Therapeutics (ZVRA) Competitors $8.62 -0.41 (-4.54%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZVRA vs. GLPG, TARS, ARVN, IMCR, SYRE, XNCR, OCUL, NTLA, KNSA, and EVOShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Galapagos (GLPG), Tarsus Pharmaceuticals (TARS), Arvinas (ARVN), Immunocore (IMCR), Spyre Therapeutics (SYRE), Xencor (XNCR), Ocular Therapeutix (OCUL), Intellia Therapeutics (NTLA), Kiniksa Pharmaceuticals (KNSA), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Galapagos Tarsus Pharmaceuticals Arvinas Immunocore Spyre Therapeutics Xencor Ocular Therapeutix Intellia Therapeutics Kiniksa Pharmaceuticals Evotec Galapagos (NASDAQ:GLPG) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings. Do insiders and institutionals hold more shares of GLPG or ZVRA? 32.5% of Galapagos shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is GLPG or ZVRA more profitable? Galapagos has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Galapagos' return on equity of 0.00% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Zevra Therapeutics -342.63%-159.54%-51.50% Which has stronger earnings & valuation, GLPG or ZVRA? Galapagos has higher revenue and earnings than Zevra Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$259.40M6.81$229.12MN/AN/AZevra Therapeutics$27.46M16.52-$46.05M-$1.97-4.38 Which has more volatility and risk, GLPG or ZVRA? Galapagos has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Does the media refer more to GLPG or ZVRA? In the previous week, Zevra Therapeutics had 31 more articles in the media than Galapagos. MarketBeat recorded 36 mentions for Zevra Therapeutics and 5 mentions for Galapagos. Galapagos' average media sentiment score of 0.93 beat Zevra Therapeutics' score of 0.47 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in GLPG or ZVRA? Galapagos received 438 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 64.19% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.19% Underperform Votes26035.81% Zevra TherapeuticsOutperform Votes28100.00% Underperform VotesNo Votes Do analysts recommend GLPG or ZVRA? Galapagos presently has a consensus price target of $30.75, indicating a potential upside of 14.74%. Zevra Therapeutics has a consensus price target of $21.00, indicating a potential upside of 143.62%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 1 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.83Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryZevra Therapeutics beats Galapagos on 9 of the 17 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$453.57M$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-4.384.8266.7313.27Price / Sales16.52374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book6.489.636.455.92Net Income-$46.05M$154.43M$119.73M$225.73M7 Day Performance-4.22%-9.46%-5.13%-1.34%1 Month Performance1.06%-7.27%-2.71%1.15%1 Year Performance98.62%28.13%31.08%24.02% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.5252 of 5 stars$8.62-4.5%$21.00+143.6%+101.4%$453.57M$27.46M-4.3865Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageHigh Trading VolumeGLPGGalapagos1.6033 of 5 stars$27.56+0.9%N/A-27.5%$1.82B$259.40M0.001,123Short Interest ↓TARSTarsus Pharmaceuticals1.7501 of 5 stars$46.51-2.2%N/A+152.8%$1.77B$17.45M-10.3850Analyst ForecastAnalyst RevisionNews CoverageARVNArvinas2.3286 of 5 stars$25.34-3.7%N/A+8.1%$1.74B$78.50M-5.43445Short Interest ↓IMCRImmunocore2.9333 of 5 stars$34.17+1.2%N/A-32.6%$1.71B$249.43M-35.97497Gap DownSYRESpyre Therapeutics2.6745 of 5 stars$32.98-7.9%N/AN/A$1.70B$890,000.00-4.41100Analyst ForecastAnalyst RevisionNews CoverageXNCRXencor3.604 of 5 stars$23.61-0.4%N/A+24.4%$1.66B$168.34M-7.38280Insider SellingOCULOcular Therapeutix4.0252 of 5 stars$10.60flatN/A+340.4%$1.65B$61.10M-7.85267Analyst ForecastNews CoverageNTLAIntellia Therapeutics4.5317 of 5 stars$16.11-3.2%N/A-46.3%$1.64B$43.09M-2.96600Gap UpKNSAKiniksa Pharmaceuticals2.2751 of 5 stars$22.62-1.6%N/A+37.4%$1.63B$270.26M-161.56220EVOEvotec1.0235 of 5 stars$4.55+2.5%N/A-44.7%$1.61B$845.74M0.005,061Short Interest ↓News CoverageGap Up Related Companies and Tools Related Companies Galapagos Alternatives Tarsus Pharmaceuticals Alternatives Arvinas Alternatives Immunocore Alternatives Spyre Therapeutics Alternatives Xencor Alternatives Ocular Therapeutix Alternatives Intellia Therapeutics Alternatives Kiniksa Pharmaceuticals Alternatives Evotec Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZVRA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
